Central nervous system stimulants and drugs that suppress appetite

Scarpa, Lori L.; Kshatriya, Dushyant; Bello, Nicholas T.

doi:10.1016/bs.seda.2021.09.010

Cited by 1 publication

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current medication achieves weight loss via multiple routes of mechanism. To be more specific, orlistat binds to gastric and pancreatic lipase to inhibit lipid absorption; phentermine-topiramate and naltrexone-bupropion suppress appetite via neuropathic mechanisms; while liraglutide and semaglutide act as GLP-1 receptor agonists. − According to a network meta-analysis published in the Lancet, antiobesity drugs exhibited body weight loss of 1.88% to up to 11.41%, with the interpretation that phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight when taking into account adverse effects …”

Section: Pharmaceuticals and Polymeric Biomaterials Carriersmentioning

confidence: 99%

Current Role and Potential of Polymeric Biomaterials in Clinical Obesity Treatment

2023

View full text Add to dashboard Cite

The rise of obesity and associated fatal diseases has taken a massive toll worldwide. Despite the existing pharmaceuticals and bariatric surgeries, these approaches manifest limited efficacy or accompany various side effects. Therefore, researchers seek to facilitate the prolonged and specific delivery of therapeutics. Or else, to mimic the essential part of "gastric bypass" by physically blocking excessive absorption via less invasive methods. To achieve these goals, polymeric biomaterials have gained tremendous interest recently. They are known for synthesizing hydrogels, microneedle patches, mucoadhesive coatings, polymer conjugates, and so forth. In this Review, we provide insights into the current studies of polymeric biomaterials in the prevention and treatment of obesity, inspiring future improvements in this regime of study.

show abstract